Member Info for BasilAlderman

Helium IS the new gold, you quite right. It is essential to hi-tech products such as computer and smartphone components, MRI systems, medical treatments, superconducting magnets, fibre optic cables, microscopes, particle accelerators and space rocket launches – NASA is a major customer. A JV or takeover of HE1 could be on the cards. There are multiple billion dollar global players who will want to monetise what HE1 are potentially sitting on.

Rahul Dhir, CEO of Tullow Oil is a big fan of our CEO:

“Lorna is an excellent Geoscientist - focussed on finding oil! She has a comprehensive understanding of the entire exploration workflow and is a real thought leader. I have been particularly impressed with her ability to challenge orthodoxy and to think creatively. She takes complete ownership of outcomes and is very committed. Also a wonderful and collaborative team player ”

Rahul Dhir, CEO of Tullow Oil

A JV with a global helium player would see the HE1 share price sky rocket. Helium major players such as Exxon, APD, Linde etc will know all about HE1's success at Itumbula. There are many multi billion players in our sector who would be able to afford to buy HE1.

Investors that have completed their DD on HE1 will know the following but for those that are unaware here are a few facts: 1. Helium is priced at up to 50 times the price of LNG in liquid form. 2. It is essential to hi-tech products such as computer and smartphone components, MRI systems, medical treatments, superconducting magnets, fibre optic cables, microscopes, particle accelerators and space rocket launches – NASA is a major consumer. 3. Rising demand and constrained supply are fuelling growth prospects within the global marketplace, particularly for cleaner “green helium” sourced from noncarbon environments. 4. At present, more than 95% of the world’s helium is produced as a by-product of the processing of hydrocarbon-bearing gas. 5. HE1's CEO's options are priced at 6.25p. 6. The current annual global demand for helium is 6.6 Bcf in a US$7 billion market. 7. Helium prices continue to rise due to the current shortage and with a global average import price of US$457 per thousand cubic feet (2023 prices and higher now). 8. Air Products and Chemicals Inc (NYSE:APD)is one of the largest helium producing companies and has a current market cap of $64 billion. 9. Exxon Mobil is responsible for providing 20% share in global helium production. 10. Helium players such as Exxon, APD, Linde will know all about HE1's success at Itumbula. A JV with a global player would see the HE1 share price sky rocket. Food for thought and why this HE1 shareholder is holding out for a big announcement.

Short term 12-15p a share on FDA news looks to be the FDA approval trend. e.g. Amarin Corp gained over 300% in one day on FDA approval. Madrigal Pharmaceutical's share price went up over 400%. Then there's Reata soaring 178% on FDA approval and Kala shares soaring 266% on FDA approval. However, I'm am in agreement with JustHereForHemo that x 10 is also very possible with HEMO climbing to over 30p this year.

A positive FDA RNS once we've achieved 5p a share would be preferable. We would most likely then climb to 12-15p, at least. I remember the Sareum 2000/2001 days from 0.3 to 9p and things really flew once the RNS' of HNWI's and positive data were unveiled. I can see this being replicated here. A x 30 was achieved at Sareum in the end. Many rises on the back of FDA approval have been 300%-400%. The higher the HEMO share price pre-news the better in my opinion.

The premium buyers have done their due diligence and have read the RNS about "Elevated hydrogen showing over 2,000 times above background" and "Elevated helium showing over 20 times above background" and have made their minds up that this is going to be very BIG. They know that they are on to a winner in the coming weeks. On good news it's not unreasonable to expect HE1 to multibag considerably. 10p+ is what I'm expecting.

We've also seen SAR go up x 30. Anything is possible once we achieve FDA status and become a clinical company. There's also the opportunity of a licencing deal to factor in as well in due course.

JustHereForHemo's "10x share price over the coming weeks" is an interesting point. That would be a share price for HEMO of 33p. We've seen many share prices soar by these kind of multiples. POS x 10, TPST x 39, ARB x 60, NCYT x 100, SNG x30, PYC x 30. Big gains do happen and HEMO could be next.

ENET went x 18 from .25p to 4.5p in 1 week 3 months ago. Big gains do happen. Expecting the same here with HE1.

UPL went from .5 to 5p. It happened quickly and HE1 has a similar vibe.I wouldn’t be surprised to see HE1 at 10p on positive news, which would only be a few multibags from the intra-day price today.

12-15p a share on FDA news is, I feel, more realistic. e.g. Amarin Corp gained over 300% in one day on FDA approval (A x 3 for Hemo would be 12p a share). Madrigal Pharmaceutical's share price went up over 400% (A x 4 would be 15p a share).

Over the next 12 months we could see a prolonged rise in the Hemo share price, such as the x54 gain at Axsome which rose from $2 per share to $108 dollars in just 12 months.

When you get an RNS that states "Elevated hydrogen shows over 2,000 times above background" and "Elevated helium shows over 20 times above background" you know you are on to a winner. A 10p a share target is only x 4 from this morning's share price. On good news it's not unreasonable to expect it to multibag considerably from here.

We have all seen the mega rises including the x 39 rise in 2 trading days at TPST. POS x 10, ARB x 60, SAR x 30, Axsome x 54, NCYT x 100 plus PYC x 34 in 4 trading days. With the right kind of news 10p for HE1 is realistic. There are likely to be a few sellers but lth's know what's possible here & the newbies will be expecting their gains too. If the next RNS is good then 10p might look cheap!

We have all seen the x 10 with POS, x 15 with GGP, x 30 with SAR, x 39 with TPST x 100 with NCYT etc. Unloved stocks suddenly become turnaround stocks. HE1 is very much falling in to this category.

Looking at the AIM big risers HE1 could be joining these soon -

BOTB went up 7,130%

GGP went up 6,300%

EUA went up 3,650%

VCP went up 6,312%

ESG went up 4,190%

What can HE1 achieve. 10p+ on news?

Mega gains do happen. ARB went from 5p to over 300p. A x 60 gain. With 1.5p achieved yesterday lets hope we see 3p today or tomorrow. Then 10p is within our grasp short term. Some of the big gains recently have been sensational. e.g. Tempest Therapeutics surged x 39 in 2 days a couple of months ago and we all know that a while back PYC went from 1p to 30p in 4 days. The best example to flag up is NCYT, which went rapidly from 12p to 1200p. i.e. x 100. we have very similar vibes and volume with HE1 currently. If we get positive news and HE1 is at 3p (which could be achieved today or tomorrow) then the 10p predictions and hopes could become a reality.

ARB went from 5p to over 300p. A x 60 gain. With 1.5p achieved today lets hope we see 3p on Tuesday. Then 10p is within our grasp short term.

10p is very possible for HE1 over the coming trading days. Tempest Therapeutics surged x 39 in 2 days a couple of months ago and we all know that PYC went from 1p to 30p in 4 days. If we get positive news and HE1 is at 3.5p (which could be achieved tomorrow now that we are at 1.50p) then 10p here we come. These kind of mega gains do happen, as we have seen in the past.

NCYT went from 12p to 1200p. i.e. x 100. Very similar vibes and volume with HE1 currently.